The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial

The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial

The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a...

Full description

Bibliographic Details
Main Authors: Somsouk, Ma, Dunham, Richard M., Cohen, Michelle, Albright, Rebecca, Abdel-Mohsen, Mohamed, Liegler, Teri, Lifson, Jeffrey, Piatak, Michael, Gorelick, Robert, Huang, Yong, Wu, Yuaner, Hsue, Priscilla Y., Martin, Jeffrey N., Deeks, Steven G., McCune, Joseph M., Hunt, Peter W.
Format: Online
Language:English
Published: Public Library of Science 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283685/
id pubmed-4283685
recordtype oai_dc
spelling pubmed-42836852015-01-07 The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial Somsouk, Ma Dunham, Richard M. Cohen, Michelle Albright, Rebecca Abdel-Mohsen, Mohamed Liegler, Teri Lifson, Jeffrey Piatak, Michael Gorelick, Robert Huang, Yong Wu, Yuaner Hsue, Priscilla Y. Martin, Jeffrey N. Deeks, Steven G. McCune, Joseph M. Hunt, Peter W. Research Article The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a placebo-controlled trial. We randomized 33 HIV-infected subjects with CD4 counts <350 cells/mm3 and plasma HIV RNA levels <40 copies/ml on antiretroviral therapy (ART) to add mesalamine vs. placebo to their existing regimen for 12 weeks followed by a 12 week crossover to the other arm. Compared to placebo-treated subjects, mesalamine-treated subjects did not experience any significant change in the percent CD38+HLA-DR+ peripheral blood CD4+ and CD8+ T cells at week 12 (P  = 0.38 and P  = 0.63, respectively), or in the CD4+ T cell count at week 12 (P  = 0.83). The percent CD38+HLA-DR+ CD4+ and CD8+ T cells also did not change significantly in rectal tissue (P  = 0.86, P  = 0.84, respectively). During the period of mesalamine administration, plasma sCD14, IL-6, D-dimer, and kynurenine to tryptophan ratio were not changed significantly at week 12 and were similarly unchanged at week 24. This study suggests that, at least under the conditions studied, the persistent immune activation associated with HIV infection is not impacted by the anti-inflammatory effects of mesalamine. Public Library of Science 2014-12-29 /pmc/articles/PMC4283685/ /pubmed/25545673 http://dx.doi.org/10.1371/journal.pone.0116306 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Somsouk, Ma
Dunham, Richard M.
Cohen, Michelle
Albright, Rebecca
Abdel-Mohsen, Mohamed
Liegler, Teri
Lifson, Jeffrey
Piatak, Michael
Gorelick, Robert
Huang, Yong
Wu, Yuaner
Hsue, Priscilla Y.
Martin, Jeffrey N.
Deeks, Steven G.
McCune, Joseph M.
Hunt, Peter W.
spellingShingle Somsouk, Ma
Dunham, Richard M.
Cohen, Michelle
Albright, Rebecca
Abdel-Mohsen, Mohamed
Liegler, Teri
Lifson, Jeffrey
Piatak, Michael
Gorelick, Robert
Huang, Yong
Wu, Yuaner
Hsue, Priscilla Y.
Martin, Jeffrey N.
Deeks, Steven G.
McCune, Joseph M.
Hunt, Peter W.
The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial
author_facet Somsouk, Ma
Dunham, Richard M.
Cohen, Michelle
Albright, Rebecca
Abdel-Mohsen, Mohamed
Liegler, Teri
Lifson, Jeffrey
Piatak, Michael
Gorelick, Robert
Huang, Yong
Wu, Yuaner
Hsue, Priscilla Y.
Martin, Jeffrey N.
Deeks, Steven G.
McCune, Joseph M.
Hunt, Peter W.
author_sort Somsouk, Ma
title The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial
title_short The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial
title_full The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial
title_fullStr The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial
title_full_unstemmed The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial
title_sort immunologic effects of mesalamine in treated hiv-infected individuals with incomplete cd4+ t cell recovery: a randomized crossover trial
description The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a placebo-controlled trial. We randomized 33 HIV-infected subjects with CD4 counts <350 cells/mm3 and plasma HIV RNA levels <40 copies/ml on antiretroviral therapy (ART) to add mesalamine vs. placebo to their existing regimen for 12 weeks followed by a 12 week crossover to the other arm. Compared to placebo-treated subjects, mesalamine-treated subjects did not experience any significant change in the percent CD38+HLA-DR+ peripheral blood CD4+ and CD8+ T cells at week 12 (P  = 0.38 and P  = 0.63, respectively), or in the CD4+ T cell count at week 12 (P  = 0.83). The percent CD38+HLA-DR+ CD4+ and CD8+ T cells also did not change significantly in rectal tissue (P  = 0.86, P  = 0.84, respectively). During the period of mesalamine administration, plasma sCD14, IL-6, D-dimer, and kynurenine to tryptophan ratio were not changed significantly at week 12 and were similarly unchanged at week 24. This study suggests that, at least under the conditions studied, the persistent immune activation associated with HIV infection is not impacted by the anti-inflammatory effects of mesalamine.
publisher Public Library of Science
publishDate 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283685/
_version_ 1613173150119362560

Similar Items